JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 96 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.12 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $1,260,000 | -20.2% | 254,590 | 0.0% | 0.04% | -21.7% |
Q1 2019 | $1,578,000 | +82.6% | 254,590 | -0.7% | 0.05% | +31.4% |
Q4 2018 | $864,000 | -68.8% | 256,473 | -39.7% | 0.04% | -58.8% |
Q3 2018 | $2,765,000 | -70.3% | 425,415 | -65.0% | 0.08% | -73.1% |
Q2 2018 | $9,304,000 | -64.8% | 1,214,593 | +2.7% | 0.32% | -69.0% |
Q1 2018 | $26,426,000 | +111.4% | 1,182,393 | +20.6% | 1.02% | +87.8% |
Q4 2017 | $12,500,000 | -16.0% | 980,393 | +2.6% | 0.54% | -26.0% |
Q3 2017 | $14,888,000 | -6.8% | 955,598 | -16.1% | 0.73% | -24.5% |
Q2 2017 | $15,971,000 | -29.1% | 1,138,370 | +2.2% | 0.97% | -33.5% |
Q1 2017 | $22,523,000 | – | 1,114,160 | – | 1.46% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |